BCLIBrainstorm Cell Therapeutics
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics (NASDAQ:BCLI) focuses on developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases. Central to their operation is NurOwn, their flagship technology platform, which is currently undergoing advanced clinical trials targeting conditions such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Parkinson's Disease. Their goal is to harness the transformative potential of stem cells to offer new hope and potentially effective treatments to patients with few other options. Through rigorous research and passionate commitment to their objectives, Brainstorm is dedicated to leading the way in stem cell therapeutic applications and improving the quality of life for patients around the globe.
What is BCLI known for?
Snapshot
Public US
Ownership
2000
Year founded
42
Employees
New York, United States
Head office
1 of 4
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
New York City, US
Produtos e/ou serviços de Brainstorm Cell Therapeutics
- NurOwn® - A cellular therapy derived from autologous mesenchymal stem cells for treating ALS and multiple sclerosis, currently in advanced clinical trials.
- MSC-NTF cells - Focuses on producing neurotrophic factors for neurodegenerative diseases' treatment.
- Platform Technology - Provides a basis for developing cellular therapies aimed at various neurodegenerative disorders.
- ALS Clinical Trials - Conducts groundbreaking studies to evaluate the efficacy and safety of NurOwn® in amyotrophic lateral sclerosis patients.
- Multiple Sclerosis Program - Explores the potential of NurOwn® in treating multiple sclerosis through clinical research.
- Regenerative Medicine Research - Engages in cutting-edge research to advance the field of regenerative medicine, particularly focusing on neurodegenerative diseases.
equipe executiva do Brainstorm Cell Therapeutics
- Mr. Chaim LebovitsPresident & CEO
- Dr. Ibrahim Dagher M.D.Executive VP & Chief Medical Officer
- Mr. Uri YablonkaExecutive VP, Chief Business Officer, Secretary & Director
- Ms. Alla Patlis CPA, M.B.A.Interim CFO & Controller
- Dr. Hartoun Hartounian Ph.D.Executive VP & COO
- Dr. Daniel Offen Ph.D.Chief Scientific Advisor
- Ms. Mary Kay TurnerSenior Vice President of Patient Advocacy & Government Affairs
- Dr. Netta Blondheim-Shraga Ph.D.Senior Vice President of Research and Development